Sterling Investment Advisors (Pennsylvania)’s Corcept Therapeutics CORT Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,000	Closed	-$141K	–	410
2019 Q3	$141K	Buy	10,000 +4,000	+67%	+$49.2K	0.07%	130
2019 Q2	$67K	Hold	6,000	–	–	0.03%	182
2019 Q1	$70K	Hold	6,000	–	–	0.04%	181
2018 Q4	$80K	Buy	6,000 +2,000	+50%	+$26.4K	0.05%	155
2018 Q3	$56K	Hold	4,000	–	–	0.03%	212
2018 Q2	$62K	Buy	4,000 +1,000	+33%	+$17.4K	0.04%	185
2018 Q1	$49K	Buy	+3,000	New	+$55.6K	0.03%	195

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s CORT Position: Q4 2019 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Corcept Therapeutics (CORT) in Q4 2019, closing a stake of 10,000 shares — an estimated $141K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in CORT in Q1 2018 and held it in 7 quarters. The position peaked at $141K in Q3 2019. 205 funds tracked by Wall St. Rank hold CORT as of Q4 2019.

Sterling Investment Advisors (Pennsylvania) reported no remaining Corcept Therapeutics position as of Q4 2019 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 10,000 Corcept Therapeutics shares in Q4 2019, an estimated $141K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Corcept Therapeutics in Q1 2018 and held it in 7 quarters.
Sterling Investment Advisors (Pennsylvania)'s Corcept Therapeutics position peaked at $141K in Q3 2019.
205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2019.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q4 2019, filed 10 Feb 2020.